antibodies -online.com







anti-IGHG4 antibody





| () | 1 / | \sim | KI / | 110 | Νę |
|-----|-----|----------|------|-----|-------|
| | 1// | \vdash | I \/ | 1 ← | ٠// ٢ |
| | | | | | |

| Quantity: | 100 μg | |
|--------------|--------------------------------------------------------------------------|--|
| Target: | IGHG4 | |
| Reactivity: | Human | |
| Host: | Mouse | |
| Clonality: | Monoclonal | |
| Conjugate: | This IGHG4 antibody is un-conjugated | |
| Application: | Immunohistochemistry (IHC), Immunostaining (ISt), Staining Methods (StM) | |

Product Details

| Immunogen: | Recombinant human IGHG4 fragment | |
|---------------|----------------------------------|--|
| Clone: | IGHG4-1345 | |
| Isotype: | IgG1 kappa | |
| Purification: | Purified by Protein A/G | |

Target Details

| Target: | IGHG4 | |
|-------------------|--------------------------------------------------------------------------------------------------|--|
| Alternative Name: | IGHG4 (IGHG4 Products) | |
| Background: | The regions of relatively constant sequence beyond the variable regions of immunoglobulins | |
| | are termed constant regions (C regions) and are present in both the heavy and light chains. | |
| | With very few exceptions, the sites of attachment for carbohydrates on immunoglobulins are | |
| | located in these C regions. These regions also function to hold the variable regions together by | |

using the disulfide bond between them. The C regions facilitate interaction with the antigen by increasing the maximum rotation of the immunoglobulin arms. Reportedly, a large population of patients with recurrent respiratory tract infection has low IgG4 concentrations. IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells.IgG4 is overexpressed in inflammatory pseudotumor (IPT) and under expressed in inflammatory myofibroblastic tumor (IMT). In pulmonary nodular lymphoid hyperplasia (PNLH), there are an increased number of IgG4+ plasma cells.

Molecular Weight: 150kDa

Gene ID: 3503

UniProt: P01861

Application Details


Application Notes: Positive Control: Tonsil.

Known Application: Immunohistochemistry (Formalin-fixed) (0.5-1.0 μ g/mL for 30 minutes at RT)(Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0 for 10-20 min followed by cooling at RT for 20 minutes)Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only


Handling

| Concentration: | 200 μg/mL | |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| Buffer: | 10 mM PBS with 0.05 % BSA & 0.05 % azide. | |
| Preservative: | Sodium azide | |
| Precaution of Use: | This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. | |
| Storage: | 4 °C,-80 °C | |
| Storage Comment: | Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required. | |
| Expiry Date: | 24 months | |



SDS-PAGE

Image 1. SDS-PAGE Analysis IgG4 Mouse Monoclonal Antibody (IGHG4/1345). Confirmation of Purity and Integrity of Antibody.



Immunohistochemistry

Image 2. Formalin-fixed, paraffin-embedded human Tonsil stained with IgG4 Mouse Monoclonal Antibody (IGHG4/1345).